Samsung Biologics Sets Out Growth Plans

Eyes CDMO Manufacturing Expansion As Samsung Bioepis Advances

 
• By Dave Wallace

Samsung Biologics has set out growth plans – including for its Samsung Bioepis biosimilars venture and its CDMO business – after its sales passed the KRW1trn threshold in 2020.

Target Dart Dartboard Data
Samsung Biologics Sees Its Sales Hit The KRW1trn Target • Source: Shutterstock

More from Strategy

More from Business